TARA — Protara Therapeutics Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Protara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$4.76
Market Cap$268M
Float49.5M
Shares Outstanding56.2M
vs. Analyst Target+458.2% to analyst PT
Dividend RateNone
Analyst Target Price$26.57 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$34.0M -$196,000 -$33.8M
2021 N/A -$47.3M -$1.2M -$45.4M
2022 N/A -$66.0M -$247,000 -$64.6M
2023 N/A -$40.4M -$341,000 -$43.3M
2024 N/A -$44.6M -$332,000 -$48.8M
2025 N/A -$57.4M -$362,000 -$64.2M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$15.0M
Sep 2025 N/A -$13.3M
Dec 2025 N/A -$17.3M
Mar 2026 N/A -$17.8M

Ownership & Float

Insider Ownership2.4%
Institutional Ownership82.3%
Short Float12.1%
% of All Funds Holding1.22%
Number of Funds Holding100

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$5.10Near-term / short-term trend
Weekly40-Week SMA$5.31Medium-term trend
Weekly80-Week SMA$4.61Cyclical trend (business cycle)
Weekly200-Week SMA$3.46Secular trend (multi-year)
Monthly10-Month SMA$5.41Near-term monthly trend
Monthly20-Month SMA$4.52Medium-term monthly trend
Monthly40-Month SMA$3.54Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$7.20 resistance 2.37x 4 months ago
$3.00 support 7.46x 16 months ago

Historical Earnings Reactions (47 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.26% 0.55% 53.19% 8.16% -8.54%
1 Day -0.68% -0.64% 42.55% 18.32% -12.25%
1 Week 0.41% -1.72% 40.43% 58.54% -19.05%
2 Weeks 4.73% 3.21% 56.52% 97.11% -85.77%
1 Month 3.31% 1.39% 52.17% 114.34% -84.94%

Next earnings: August 1, 2026 (65 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan11.2%66.7%12
Feb-1.0%33.3%12
Mar-5.9%41.7%12
Apr-9.2%41.7%12
May5.3%27.3%11
Jun-2.2%45.5%11
Jul-4.7%36.4%11
Aug-3.1%45.5%11
Sep-2.1%27.3%11
Oct1.3%45.5%11
Nov14.4%83.3%12
Dec4.0%50.0%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.13% 44.4% 545
Tuesday 0.00% 44.6% 601
Wednesday 0.43% 47.4% 597
Thursday -0.12% 42.4% 585
Friday -0.03% 42.6% 585

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 82.3%

Insider Transactions — Smart Summary

Total insider ownership: 2.4%

Founder-led management: Jesse Shefferman (Chief Executive Officer), Jacqueline Zummo (Chief R&D Officer)

12-Month Insider Activity Summary

Total Filings2
Net Value-$124,989.08
Net Shares Change-23,732
% of Float-0.0%
C-Suite Filings2
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Zummo Jacqueline Chief RandD Officer -$124,989.08 2 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-04-02 Zummo Jacqueline Chief RandD Officer -$118,865.48 Transaction at $5.26, now -9.5%
2026-04-09 Zummo Jacqueline Chief RandD Officer -$6,123.6 Transaction at $5.40, now -11.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Protara Therapeutics Inc (TARA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for TARA on Trend Edge →